{"id":"W6958786032","doi":"10.6084/m9.figshare.c.6578789","title":"INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)","year":2023,"lang":"en","type":"other","venue":"Figshare","topic":"Particle accelerators and beam dynamics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Regorafenib; Nivolumab; Clinical endpoint; Adverse effect; Placebo; Refractory (planetary science); Clinical trial; Phases of clinical research; Bevacizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00654246,0.002966633,0.005116027,0.0008283112,0.0005869687,0.001901408,0.001604188,0.002760423,0.008668525],"category_scores_gemma":[0.005269606,0.00110852,0.004740745,0.00098655,0.001731297,0.001413963,0.0008080286,0.003319423,0.001140266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001427259,"about_ca_system_score_gemma":0.001919836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001303051,"about_ca_topic_score_gemma":0.002984341,"domain_scores_codex":[0.9972019,0.001737689,0.0002416232,0.000379684,0.0002176835,0.0002213444],"domain_scores_gemma":[0.9973229,0.0007709627,0.0009147571,0.0002459716,0.0002343504,0.000511172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821995,0.004331851,0.0002775539,0.002082594,0.002375496,0.00002521445,0.00003629054,0.0002510544,0.001275975,0.0001405739,0.0007076612,0.006296227],"study_design_scores_gemma":[0.9690682,0.0290256,0.0004433652,0.0000613983,0.0006428093,0.000009852794,0.00001096327,0.00009380703,0.00009929706,0.00008592256,0.000450403,0.000008361799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8468832,0.03918736,0.003760237,0.002276538,0.003293773,0.09103102,0.006127296,0.0005177687,0.00692272],"genre_scores_gemma":[0.8590331,0.01204274,0.007211094,0.003975474,0.001992258,0.1048563,0.00369891,0.00008132035,0.007108693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008668525,"threshold_uncertainty_score":0.03460026,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04777409358156592,"score_gpt":0.3431586091486369,"score_spread":0.295384515567071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}